EDIT Editas Medicine
- 5.080
- +0.170+3.46%
- 5.070
- -0.010-0.20%
Editas Medicine News
Editas Medicine Analyst Ratings
Editas Medicine Analyst Ratings
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine Analyst Ratings
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Editas Medicine's Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
Maintaining a Hold: Editas Medicine Awaits Key Clinical Trial Results and Market Positioning
Buy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth Outlook
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism
Editas Medicine: Balanced Prospects and a Hold Rating With Modest Price Target Increase
The Latest Analyst Ratings For Editas Medicine
Oppenheimer Sticks to Its Hold Rating for Editas Medicine (EDIT)
Hold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potential
Analysts' Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)
TD Cowen Sticks to Its Buy Rating for Editas Medicine (EDIT)
Editas Medicine Analyst Ratings
Buy Rating for Editas Medicine Backed by Strong SCD Program and Promising Clinical Developments
RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT)
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating
Analysis
Price Target
No Data
